SUSTAINED BENEFIT WITH SERALUTINIB TREATMENT: A POST-HOC ANALYSIS OF THE TORREY OPEN-LABEL EXTENSION

SUSTAINED BENEFIT WITH SERALUTINIB TREATMENT: A POST-HOC ANALYSIS OF THE TORREY OPEN-LABEL EXTENSION

PVRILatam – Nov 2024c

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study